Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
Go back to Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)| Regeneron (NASDAQ: REGN) | Delayed: 651.18 -24.01 (3.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $675.19 | 52 Week High | $592.36 | |||
| Open | $676.43 | 52 Week Low | $325.35 | |||
| Day High | $676.80 | P/E | 170.91 | |||
| Day Low | $648.90 | EPS | $3.81 | |||
| Volume | 872,169 | |||||
| Regeneron (NASDAQ: REGN) | Delayed: 651.18 -24.01 (3.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $675.19 | 52 Week High | $592.36 | |||
| Open | $676.43 | 52 Week Low | $325.35 | |||
| Day High | $676.80 | P/E | 170.91 | |||
| Day Low | $648.90 | EPS | $3.81 | |||
| Volume | 872,169 | |||||
